A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia

Drugs and Aging

Volumn 23, Issue 3, 2006, Pages 241-249

  Potkin, Steven G ^a   Alva, Gus ^a   Gunay, Ibrahim ^b   Koumaras, Barbara ^b   Chen, Michael ^b   Mirski, Dario ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; APPETITE DISORDER; ARTICLE; ASTHENIA; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIARRHEA; DISTRACTIBILITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FALLING; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MENTAL CONCENTRATION; MENTAL DISEASE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NAUSEA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT INFORMATION; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TITRIMETRY; WEIGHT REDUCTION;

ADULT; AGED; COGNITION; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 33645756362     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623030-00006     Document Type: Article

References (50)

1. Nyenhuis DL, Gorelick PB. Vascular dementia: a contemporary review of epidemiology, diagnosis, prevention, and treatment. J Am Geriatr Soc 1998; 46: 1437-48
2. Roman GC. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 2003 May; 51 (5 Suppl Dementia): S296-304
3. O'Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol 2003; 2: 89-98
4. Gorelick PB, Nyenhuis DL, Garron DC, et al. Is vascular dementia really Alzheimer's disease or mixed dementia? Neuroepidemiol 1996; 15: 286-90
5. Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 2002; 50: 1431-8
6. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60
7. de la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152-62
8. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004; 3: 184-90
9. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-8
10. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000; 21: 331-42
11. Kudo T, Imaizumi K, Tanimukai H, et al. Are cerebrovascular factors involved in Alzheimer's disease? Neurobiol Aging 2000; 21: 215-24
12. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging 2000; 21: 321-30
13. Shi J, Perry G, Smith MA, et al. Vascular abnormalities: the insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 2000; 21: 357-61
14. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153-60
15. Roman GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging. Epub 2005 Nov 21
16. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular funcrisk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56: 1683-9
17. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51
18. Panza F, D'Introno A, Colacicco AM, et al. Vascular risk and genetics of sporadic late-onset Alzheimer's disease. J Neural Transm 2004; 111: 69-89
19. de la Torre JC. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci 1997; 826: 75-91
20. de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci 2000; 924: 136-52
21. Hatanpaa K, Brady DR, Stoll J, et al. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1996; 40: 411-20
22. Duara R, Barker WW, Chang J, et al. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab 1992; 12: 927-34
23. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882-91
24. Davies KL, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease [letter]. Lancet 1976; 2: 1403
25. Szilagyi AK, Nemeth A, Martini E, et al. Serum and CSF cholinesterase activity in various kinds of dementia. Eur Arch Psychiatry Neurol Sci 1987; 236: 309-11
26. Hamel E. Cholinergic modulation of the cortical microvascular bed. Prog Brain Res 2004; 145: 171-8
27. Sato A, Sato Y, Uchida S. Activation of the intracerebral cholinergic nerve fibers originating in the basal forebrain increases regional cerebral blood flow in the rat's cortex and hippocampus. Neurosci Lett 2004; 361: 90-3
28. Sato A, Sato Y, Uchida S. Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain. Int J Dev Neurosci 2001; 19: 327-37
29. Blin J, Ivanoiu A, Coppens A, et al. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer's disease patients. Neuroimage 1997; 6: 335-43
30. Domino EF, Minoshima S, Guthrie S, et al. Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse 2000; 38: 313-21
31. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Ann Nucl Med 2001; 15: 85-92
32. Nakano S, Asada T, Matsuda H, et al. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 2001; 42: 1441-5
33. Vennerica A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13: 83-7
34. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4: 273-7
35. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002; 9: 88-93
36. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8
37. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Psychopharmacol 1998; 1: 55-65
38. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7: 486-8
39. Kumar V, Anand R, Messina J, et al. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-69
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000
41. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44
42. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
43. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
44. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S22-32
45. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
46. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-9
47. DeJong R. Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin Ther 1989; 11: 545-54
48. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-6
49. Suh GH, Ju YS, Yeon BK, et al. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 2004; 19: 817-24
50. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90